Medicus Pharma Ltd. (NASDAQ:MDCX)
| Market Cap | $1.63M-98.8% |
| Revenue (ttm) | $0 |
| Net Income | -$44.03M-49.1% |
| EPS | -$58.61+24.9% |
| Shares Out | 1.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,719 |
| Open | $1.09 |
| Previous Close | $1.16 |
| Day's Range | $1.09 - $1.20 |
| 52-Week Range | $1.06 - $114.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $1.00(-11.89%) |
| Earnings Date | Mar 24, 2027 |
About MDCX
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Next catalysts
- Mar 24, 2027Earnings report
$MDCX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MDCX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MDCX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MDCX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MDCX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MDCX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from MDCX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Regained Nasdaq compliance, secured $4.25M financing, executed $10.5M debt exchange, and strengthened pipeline focus on Pfizer-licensed cancer drug amid cost optimization.
